{"favorite_id": 1785, "calc_type": "calculator", "dosing": false, "full_title_en": "HEMORR\u2082HAGES Score for Major Bleeding Risk", "short_title_en": "HEMORR\u2082HAGES Score", "medium_description_en": "Quantifies risk of hemorrhage in elderly patients with AFib.", "short_description_en": "Bleeding risk in elderly AF.", "before_use": "", "instructions_en": "<p>The HEMORR<sub>2</sub>HAGES Score was developed using ICD-9 data; while we are actively reaching out to its study authors, the terms included in the score are not defined in the study.</p>", "slug": "hemorr2hages-score-major-bleeding-risk", "logic_language": "javascript", "md5": "9f28012599d9e4ca925cd6e64c554560", "cmeVersion": "1785.1", "cmeReleaseDate": "2020-06-07 00:00:00+00+00", "cmeEndDate": "2025-07-25 00:00:00+00+66", "cmeLastReviewed": "2022-07-25 00:00:00+00+66", "search_abbreviation_en": ["hemorr2hages", "bleeding", "coumadin", "warfarin", "afib", "stroke risk"], "seo": {"meta_description_en": "The HEMORR2HAGES Score quantifies the bleeding risk for elderly patients with atrial fibrillation who are anticoagulated with coumadin/warfarin.", "keywords_en": "Hemorrhage risk, hemorrhage risk calculator, hemorrhage elderly, hemorrhage elderly risk, hemorrhage afib risk, elderly afib risk, hemorr2, hemorr2hages, bleed risk elderly, bleed risk elderly score, hemorrhages atrial fibrillation risk, hemorr2hages risk calculator"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"videos": [], "sdm_tool": [], "teaching": [], "interests": [{"link": "https://www.mdcalc.com/stroke-risk-atrial-fibrillation-practice-pearls", "text": "Practice Pearls: Atrial Fibrillation and Stroke Risk", "description": "Evidence syntheses and practical tips on management of atrial fibrillation"}], "guidelines": [], "mdcalc_rating": {"clinical": "", "evidence": "", "popularity": ""}, "partner_contact": []}, "how_to_use": {"use_case_en": "<p>Consider using the HEMORR<sub>2</sub>HAGES score to stratify patients&rsquo; risk for bleeding after anticoagulation for atrial fibrillation in conjunction with situation specific risks/benefits.</p>", "pearls_pitfalls_en": "<p>The HEMORR<sub>2</sub>HAGES score was developed to quantify the risk of hemorrhage in patients with atrial fibrillation on anticoagulation and to aid in the management of antithrombotic therapy.</p>\n<ul>\n<li>Combined hemorrhage risk factors from three previously existing clinical prediction rules to form the HEMORR<sub>2</sub>HAGES mnemonic.</li>\n<li>Validated the score by retrospectively applying it to a cohort of patients from the National Registry of Atrial Fibrillation database.</li>\n<li>Scoring system consists of eleven criteria, one of which (history of prior bleeding) is worth 2 points, while the other ten are worth 1 point each.</li>\n<li>For the basis of comparison to other bleeding risk schemes, patients with a score of 0 or 1 were classified as low-risk, 2 or 3 intermediate-risk, &ge;4 high-risk.</li>\n<li>Study found that the number of bleeds per 100 patient-years of warfarin increased as their HEMORR<sub>2</sub>HAGES score increased.</li>\n<li>For patients on warfarin, study found that HEMORR<sub>2</sub>HAGES was more discriminatory compared to the other schemes.</li>\n</ul>\n<p><strong>Points to keep in mind:</strong></p>\n<ul>\n<li>Degree of hemorrhage was not examined in the study; all study patients with ICD-9 codes for active hemorrhage in any location were included.</li>\n<li>The genetic risk factor was included in their score, but not actually tested in their cohort of patients.</li>\n<li>There were variable definitions of hepatic or renal disease, thrombocytopenia depending on the state in which the patient lived.</li>\n<li>All data was obtained retrospectively, via chart review and ICD-9 codes. Events occurring outside of the hospital or coded incorrectly were not included.</li>\n<li>Anemia, malignancy and uncontrolled hypertension were included in a patient&rsquo;s score if they were entered in as ICD-9 diagnoses, regardless if they were clinically important or not (e.g. distant history of cancer which has been in complete remission would still count as malignancy by ICD-9).</li>\n<li>Excessive fall risk was determine by chart review for &ldquo;high risk of falling, dementia, Parkinson's disease, or psychiatric disease.&rdquo;</li>\n<li>Study also examined ASA usage, but does not present specific data on the risk of hemorrhage on ASA with different HEMORR<sub>2</sub>HAGES scores.</li>\n<li>There was no comparison to more recently derived bleeding risk scores such as <calculator id=\"1718\">ATRIA</calculator> or <calculator id=\"807\">HAS-BLED</calculator>.</li>\n</ul>\n<p>A subsequent systemic review and meta-analysis comparing the performance of <calculator id=\"807\">HAS-BLED</calculator>, <calculator id=\"1718\">ATRIA</calculator> and HEMORR<sub>2</sub>HAGES recommended HAS-BLED for the assessment of atrial fibrillation patients&rsquo; major bleeding risk. The analysis found that HEMORR<sub>2</sub>HAGES had a higher diagnostic accuracy, but considered it difficult to use due to its complexity.</p>", "why_use_en": "<p>Combines components from several other previously validated bleeding risk scores into one.</p>"}, "next_steps": {"advice_en": "", "management_en": "", "critical_actions_en": "<ul>\n<li>Risks and benefits of anticoagulation should be carefully considered in ALL patients prior to initiating therapy.</li>\n<li>Other risk stratification scores such as <calculator id=\"807\">HAS-BLED</calculator> or <calculator id=\"1718\">ATRIA</calculator> should also be taken into consideration prior to starting anticoagulation.</li>\n<li>Alternative options should often be considered in patients with high-risk of major bleeding events in need of anticoagulation.</li>\n</ul>"}, "about": {"formula_en": "<p>Addition of the selected points, see below:</p>", "more_info_en": "<div class=\"table-responsive\">\n<table class=\"table table-bordered\">\n<tbody>\n<tr>\n<th>Criteria</th>\n<th>Points</th>\n</tr>\n<tr>\n<td>Hepatic or renal disease</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Ethanol abuse</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Malignancy</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Older (age &gt; 75)</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Reduced platelet count or function</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Rebleeding (Prior Bleed)</td>\n<td>+2</td>\n</tr>\n<tr>\n<td>Hypertension (uncontrolled)</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Genetic factors (CYP 2C9 single-nucleotide polymorphisms)</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Excessive fall risk</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Stroke</td>\n<td>+1</td>\n</tr>\n</tbody>\n</table>\n</div>", "evidence_based_medicine_en": "<p>One meta analysis (see references, below) specifically recommends using the <calculator id=\"807\">HAS-BLED Score</calculator> over the HEMORR<sub>2</sub>HAGES Score because of the former's greater sensitivity (the latter, however, did have better specificity).</p>", "references_list": {"Validation": [{"text": "Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the use of sr34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60(9):861-867.", "href": "https://pubmed.ncbi.nlm.nih.gov/22858389/"}], "Outcomes": [{"text": "", "href": ""}], "Validations": [], "Original/Primary Reference": [{"text": "Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation. Am Heart J 2006; 151:713-9.", "href": "http://www.ncbi.nlm.nih.gov/pubmed/16504638"}], "Other References": [{"text": "Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014;40(3):277-284.", "href": "http://www.ncbi.nlm.nih.gov/pubmed/25012972"}], "Clinical Practice Guidelines": [{"text": "", "href": ""}], "Manufacturer Website": [{"text": "", "href": ""}]}}, "creator": [{"qa_en": null, "approved": null, "name": "Dr. Brian Gage", "creator_info": {"deceased": false, "about_en": "<p>Brian F. Gage, MD, MSc, is a professor of medicine at Washington University in St. Louis where he teaches Designing Outcomes & Clinical (DOC) Research and practices at Barnes-Jewish Hospital, where he directs the Clinical-Scientist Teaching And Research (C-STAR) program for medical residents. He directs the Washington University Fellowship in General Medical Sciences (GMS). Dr. Gage studies antithrombotic therapy and thrombosis, including cardioembolic stroke.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-brian-gage.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Gage%20BF%5BAuthor%5D"}}], "contributor": {"expert_name": [{"description": "<p>Calvin Hwang, MD, is a clinical assistant professor in the department of orthopaedic surgery at the Stanford University School of Medicine. A native Californian, Dr. Hwang grew up in San Diego and attended Stanford University before venturing off to Case Western Reserve University School of Medicine, where he received his medical degree. He completed his residency at the Stanford/Kaiser Emergency Medicine program and fellowship in sports medicine at Stanford. He is currently a team physician for the Golden State Warriors, Stanford Football and Stanford Volleyball.</p>", "firstName": "Calvin", "img": "calvin-hwang.jpg", "lastName": "Hwang", "name": "Calvin Hwang, MD", "target": "calvin-hwang", "signedCOI": true, "hasDisclosure": []}]}}, "input_schema": [{"type": "toggle", "name": "hepatic_renal_disease", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Hepatic or Renal Disease</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "ethanol_alcohol_abuse", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Ethanol (Alcohol) Abuse</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "malignancy", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Malignancy History</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "age_75", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Older (Age &gt; 75)</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "reduced_platelet", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Reduced Platelet Count or Function</p>", "show_points": true, "tips_en": "Includes aspirin use, any thrombocytopenia or blood dyscrasia, like hemophilia", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "rebleeding", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Rebleeding Risk</p>", "show_points": true, "tips_en": "History of past bleeding", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}]}, {"type": "toggle", "name": "hypertension", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Hypertension (Uncontrolled)</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "anemia", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Anemia</p>", "show_points": true, "tips_en": "Hgb <13 g/dL for Men; Hgb <12 g/dL for Women", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "genetic", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Genetic Factors</p>", "show_points": true, "tips_en": "CYP 2C9 single-nucleotide polymorphisms", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "fall_risk", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Excessive Fall Risk</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"type": "toggle", "name": "stroke_history", "conditionality": "", "optional": false, "default": 0, "label_en": "<p>Stroke History</p>", "show_points": true, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}], "chief_complaint_en": ["Bleeding"], "specialty_en": ["Cardiology", "Critical Care", "Emergency Medicine", "Family Practice", "Geriatrics", "Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine"], "purpose_en": ["Prognosis", "Treatment"], "system_en": ["Cardiac", "Hematologic"], "disease_en": ["Atrial Fibrillation", "Bleeding/Hemorrhage", "Intracranial Hemorrhage", "Stroke/TIA", "Subarachnoid Hemorrhage"], "related_calcs": [{"calcId": 1718, "short_title_en": "ATRIA Bleeding Risk", "slug": "atria-bleeding-risk-score"}, {"calcId": 807, "short_title_en": "HAS-BLED Score", "slug": "has-bled-score-major-bleeding-risk"}, {"calcId": 10227, "short_title_en": "ORBIT Score for Afib", "slug": "orbit-bleeding-risk-score-atrial-fibrillation"}]}